© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90668 refers to the influenza virus vaccine specifically formulated for pandemic situations. This vaccine is a split virus type, which means it is created using a method that involves breaking apart the virus particles to enhance the immune response without using live virus. The pandemic formulation is distinct from standard influenza vaccines, as it is designed to address new strains of the virus that can emerge during an influenza pandemic, when the population has little to no pre-existing immunity. The vaccine is administered via intramuscular injection, ensuring that it is delivered effectively into the muscle tissue for optimal absorption and immune response. The production of this vaccine involves several steps, including the cultivation of the virus in embryonated chicken eggs, inactivation of the virus with formaldehyde, concentration to increase the antigen content, and purification processes to ensure safety and efficacy. This vaccine is crucial in preventing widespread illness and mortality during a pandemic, as it helps to build immunity against the newly emerging strains of the influenza virus.
© Copyright 2025 Coding Ahead. All rights reserved.
The influenza virus vaccine (CPT® Code 90668) is indicated for use during a pandemic situation when a new strain of the influenza virus emerges. The following conditions and scenarios warrant the administration of this vaccine:
The administration of the influenza virus vaccine (CPT® Code 90668) involves several key procedural steps to ensure safety and efficacy:
After the administration of the influenza virus vaccine (CPT® Code 90668), patients may experience mild side effects, which are common with vaccinations. These can include soreness at the injection site, low-grade fever, or fatigue. It is important for healthcare providers to monitor patients for any adverse reactions following the vaccination. Patients are typically advised to rest and hydrate after receiving the vaccine. The expected recovery time is generally short, with most individuals returning to normal activities shortly after vaccination. Additionally, it is essential to inform patients about the importance of receiving the vaccine during a pandemic to help protect themselves and the community from the spread of the influenza virus.
| Short Descr | IIV VACCINE PANDEMIC IM | Medium Descr | IIV VACCINE PANDEMIC FOR INTRAMUSCULAR USE | Long Descr | Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Type of Service (TOS) | V - Pneumococcal/Flu Vaccine | Berenson-Eggers TOS (BETOS) | O1G - Immunizations/Vaccinations | MUE | 1 | CCS Clinical Classification | 228 - Prophylactic vaccinations and inoculations |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2016-01-01 | Changed | First appearance of change in codebook. |
| 2015-07-01 | Changed | Description Changed. FDA approval pending |
| 2011-01-01 | Added | First appearance in code book |
| 2010-07-01 | Added | Implemented |
Get instant expert-level medical coding assistance.